As previously disclosed, Genenta Science S.p.A. and Ospedale San Raffaele S.r.l. have entered into a license agreement, pursuant to which OSR has granted the Company a worldwide license, subject to certain retained rights, to certain patents, patent applications and existing know-how for the use in the field of interferon (“IFN”) gene therapy by lentiviral based-hematopoietic stem and progenitor cell gene transfer with respect to: (i) any lympho-hematopoietic indication; and (ii) any solid cancer indication that the Company exercises an option in respect of pursuant to the terms of the OSR License Agreement. In particular, the OSR License Agreement provided the Company with exclusive options (the “Options”) that were exercisable on or before December 23, 2022 to: (i) expand the license to include, upon the payment of specified option fees, certain alternative payloads (rather than IFN) and/or competing products; (ii) negotiate an additional license to certain intellectual property rights developed under the Sponsored Research Agreement the Company entered into with OSR on February 12, 2021; and (iii) convert, at no additional cost, an option to include the second solid cancer indication as part of the field of use to an indication other than solid liver cancer (“LC”), if the Company could not obtain regulatory approval to initiate a human clinical trial in any country with respect to solid LC on or before December 23, 2022. On December 22, 2022, the Company entered into a letter agreement (the “Letter Agreement”) with OSR that extended the exercise periods for the Options from December 23, 2022 to March 23, 2023.

A copy of the Letter Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing summary of the terms of the Letter Agreement is subject to and qualified in its entirety by the complete text of such document.